SwePub - search: id:"swepub:oai:lup.lub.lu.se:b...

Enumeration	Reference	Cover	Find
1.	Jerkeman, Mats, et al. (author) Long-term remission in idiopathic Castleman's disease with tocilizumab followed by consolidation with high-dose melphalan-two case studies. 2015 In: European Journal of Haematology. - : Wiley. - 1600-0609 .- 0902-4441. Journal article (peer-reviewed)abstract Multicentric Castleman's disease (MCD) is an uncommon lymphoproliferative disorder, often associated with a clinically aggressive behavior. No standard treatment has been established, but patients are usually treated with lymphoma-type regimens such as rituximab or combination chemotherapy. Recently, immunotherapies targeting IL-6 have proven effective and have been approved for this indication. However, these agents require long-term administration. Here, we describe the clinical course of two patients, refractory to rituximab and chemotherapy, showing long-term remission (18 and 24 months), following an induction phase with tocilizumab (an anti-IL-6 receptor antibody) and a consolidative phase with high-dose melphalan accompanied by autologous stem cell support. This may prove to be an effective option for this group of patients with an orphan disorder.

Jerkeman, Mats, et al. (author)
Long-term remission in idiopathic Castleman's disease with tocilizumab followed by consolidation with high-dose melphalan-two case studies.
2015
In: European Journal of Haematology. - : Wiley. - 1600-0609 .- 0902-4441.
Journal article (peer-reviewed)abstract
- Multicentric Castleman's disease (MCD) is an uncommon lymphoproliferative disorder, often associated with a clinically aggressive behavior. No standard treatment has been established, but patients are usually treated with lymphoma-type regimens such as rituximab or combination chemotherapy. Recently, immunotherapies targeting IL-6 have proven effective and have been approved for this indication. However, these agents require long-term administration. Here, we describe the clinical course of two patients, refractory to rituximab and chemotherapy, showing long-term remission (18 and 24 months), following an induction phase with tocilizumab (an anti-IL-6 receptor antibody) and a consolidative phase with high-dose melphalan accompanied by autologous stem cell support. This may prove to be an effective option for this group of patients with an orphan disorder.

Träfflista för sökning "id:"swepub:oai:lup.lub.lu.se:bb4778b6-2f94-4066-9216-85f1011a7cc5" "